Digital Healthcare growth drivers in 2019

Digital HealthcareThe US Food and Drug Administration (#FDA) has cautiously moved to embrace Digital Therapeutics, mobile trial platforms and expanded use of real world evidence (#RWE) mining for clinical development: this progress will continue to drive sponsor investment.

Substantively, the agency has issued landmark approvals of digital products including Pear’s reSET, Proteus/Otsuka’s Abilify MyCite, and earlier WellDoc’s BlueStar.

The list of companies with digital products in development that will be seeking approval is growing.

Click here for more…